Study of STLX-2012 in Healthy Volunteers
ConditionHealthy Participants
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorStelexis BioSciences
About this trial
The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.
Eligibility criteria
Qualifiers
Male or female participants aged 18-55 years old, inclusive, at Screening.
Body mass index of 18-32 kg/m², inclusive
Healthy as determined by the investigator
Adequate hepatic and renal function
Disqualifiers
Pregnant or lactating female.
Positive urine drug screen or alcohol breath test
Neutropenia, defined as neutrophil count <2.0 x 10^9/L
History of allergic reaction requiring treatment or anaphylactic reactions to any therapeutic drug.
Trial design
Treatments tested in this trial
- STLX-2012
- Placebo
Treatment groups
32 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov